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Background Registry data suggest that people with immune-mediated inflammatory
diseases (IMIDs) receiving targeted systemic therapies have fewer adverse coron-
avirus disease 2019 (COVID-19) outcomes compared with patients receiving no
systemic treatments.
Objectives We used international patient survey data to explore the hypothesis that
greater risk-mitigating behaviour in those receiving targeted therapies may
account, at least in part, for this observation.
Methods Online surveys were completed by individuals with psoriasis (globally)
or rheumatic and musculoskeletal diseases (RMDs) (UK only) between 4 May
and 7 September 2020. We used multiple logistic regression to assess the associa-
tion between treatment type and risk-mitigating behaviour, adjusting for clinical
and demographic characteristics. We characterized international variation in a
mixed-effects model.
Results Of 3720 participants (2869 psoriasis, 851 RMDs) from 74 countries,
2262 (608%) reported the most stringent risk-mitigating behaviour (classified
here under the umbrella term ‘shielding’). A greater proportion of those receiv-
ing targeted therapies (biologics and Janus Kinase inhibitors) reported shielding
compared with those receiving no systemic therapy [adjusted odds ratio (OR)
163, 95% confidence interval (CI) 135–197]. The association between tar-
geted therapy and shielding was preserved when standard systemic therapy was
used as the reference group (OR 139, 95% CI 123–156). Shielding was asso-
ciated with established risk factors for severe COVID-19 [male sex (OR 114,
95% CI 105–124), obesity (OR 137, 95% CI 123–154), comorbidity burden
(OR 143, 95% CI 115–178)], a primary indication of RMDs (OR 137, 95%
CI 127–148) and a positive anxiety or depression screen (OR 157, 95% CI
136–180). Modest differences in the proportion shielding were observed
across nations.
Conclusions Greater risk-mitigating behaviour among people with IMIDs receiving
targeted therapies may contribute to the reported lower risk of adverse COVID-
19 outcomes. The behaviour variation across treatment groups, IMIDs and
nations reinforces the need for clear evidence-based patient communication on
risk-mitigation strategies and may help inform updated public health guidelines
as the pandemic continues.
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What is already known about this topic?
• At the beginning of the coronavirus disease 2019 (COVID-19) pandemic, patients
with immune-mediated inflammatory diseases (IMIDs) on targeted systemic thera-
pies were considered to be at higher risk of severe COVID-19.
• Subsequent clinician-reported registry data suggest that targeted systemic therapy
use is associated with fewer adverse COVID-19 outcomes compared with no sys-
temic therapy.
What does this study add?
• We characterize shielding behaviour in 3720 patients with IMIDs from a global
self-report survey.
• Use of targeted systemic therapy associates with increased shielding behaviour,
compared with standard systemics or no therapy, as do demographic risk factors
for severe COVID-19 including male sex and obesity.
• Greater risk-mitigating behaviour among people with IMIDs receiving targeted thera-
pies may contribute to the reported lower risk of adverse COVID-19 outcomes.
• Behaviour variation across treatment groups reinforces the need for clear, evidence-
based patient communication on risk-mitigation strategies.
• These data may help to inform updated public health guidelines as the pandemic
continues.
The coronavirus disease 2019 (COVID-19) pandemic, caused by
the highly infectious SARS-CoV-2 virus, represents an unprece-
dented global health crisis.1,2 Death from COVID-19 is associated
with male sex, older age, Asian/Black ethnicity and coexisting
conditions including cardiovascular disease and obesity.3,4
Guided by international recommendations from the World
Health Organization (WHO), public health risk-mitigating mea-
sures such as social/physical distancing were introduced early in
the pandemic to limit community transmission of COVID-19.5–8
The WHO also recommended more stringent protection mea-
sures to reduce exposure risk in groups at higher risk of severe
COVID-19.9 This was referred to as ‘shielding’, and in the UK,
was incorporated into Government policy where individuals
classed as clinically extremely vulnerable were advised to physi-
cally isolate at home and avoid face-to-face interactions.7
Informed by pre-COVID-19 observational studies on drug-re-
lated risks of serious infection,10–13 individuals with immune-
mediated inflammatory diseases (IMIDs) receiving drugs that
affect the immune system were considered to be at higher risk of
severe COVID-19.14,15 While limited evidence has been pub-
lished to date on drug-specific COVID-19 risks in IMIDs, rheuma-
toid arthritis, systemic lupus erythematosus and psoriasis were
collectively suggested as risk factors for death using UK primary
care data linked to hospital records from 17 million adults.3 Glo-
bal clinician-reported registry data in rheumatic diseases, psoriasis
and inflammatory bowel disease have further suggested a differ-
ential risk of severe COVID-19 associated with different treatment
types. In particular, the use of targeted systemic therapies [biolog-
ics and Janus Kinase (JAK) inhibitors] was associated with a
reduced risk of adverse COVID-19 outcomes, compared with no
treatment or standard systemic agents.16–18 It remains unclear if
this is attributable to therapeutic modulation of the host antiviral
immune and inflammatory response (i.e. biological mechanisms)
or enhanced shielding behaviour in patients receiving targeted
therapies (resulting in a lower infectious dose of SARS-CoV-2).
There is an urgent need to address this knowledge gap because
targeted and standard systemic therapies represent the mainstay
of treatment in moderate-to-severe IMIDs.
Rheumatic and musculoskeletal diseases (RMDs) and psoria-
sis are common IMIDs that are closely related: psoriasis is the
commonest immune-mediated skin disease associated with
inflammatory arthritis, and both conditions have a high preva-
lence of multimorbidity and are effectively treated with tar-
geted and standard systemic therapies. We focused on RMDs
and psoriasis as representative IMIDs and used global self-re-
port survey data to explore the notion that individuals receiv-
ing different types of treatment exhibit distinct risk-mitigating
behaviours in the pandemic.
Methods
Study design, participants
Two online, self-report surveys with aligned questions, per-
mitting a combined analysis of data, were developed for peo-
ple with psoriasis [Psoriasis Patient Registry for Outcomes,
Therapy and Epidemiology of COVID-19 Infection Me (PsoPro-
tectMe): www.psoprotectme.org] and RMDs [COVID-19
Rheumatology Register (CORE-UK): https://www.redcap02.
medstats.org.uk/redcap/surveys/?s=LCA3L4JHXW].
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PsoProtectMe (available in eight different languages) was pro-
moted globally following its launch on 4 May 2020 and
CORE-UK was subsequently launched on 12 June 2020 and
promoted in the UK. The surveys were disseminated via social
media, patient organizations (Table S1; see Supporting Infor-
mation) and clinical networks. The eligibility criterion was
any person (all ages) with a clinician-confirmed diagnosis of
psoriasis (PsoProtectMe) or RMD (CORE-UK), irrespective of
COVID-19 status (REC ref 20/YH/0135). Data were collected
and managed using REDCap electronic data capture tools
licensed to King’s College London Division of Health and
Social Care Research.19
Variables
Minimum sufficient core sets of variables within the surveys
were defined by our study group of clinicians, epidemiolo-
gists, health data researchers and patient representatives. The
Patient Health Questionnaire-2 (PHQ-2) and Generalized Anx-
iety Disorder 2-item (GAD-2) scales were used to screen for
depression and anxiety, respectively; scores of 3 or more were
positive. Adherence was assessed with a single-item question
which asked if the individual had stopped or delayed their
medication in the pandemic.
Risk-mitigating behaviour was assessed with the following
question: ‘Over the past 30 days, what methods have you been using to protect
yourself from COVID-19?’ Respondents could select any of the fol-
lowing options: (1) Shielding (quarantine, strict distancing from
family members in the home); (2) Self-isolation (quarantine,
staying home, avoiding others); (3) Social distancing (avoiding
crowds and large groups of people); (4) Using gloves and/or
masks during social interactions; (5) None. The most stringent
risk-mitigating behaviour was classified under the umbrella term
‘shielding’, encompassing (1) shielding and (2) self-isolation.
‘Shielding’ was considered as a binary variable; any respondent
who selected options (1) or (2) were coded as having shielded,
and those selecting (3), (4) or (5) as having not shielded.
UK participants were also asked whether they were advised
to shield using the following question: ‘Did you receive a letter or
text from the NHS asking you to take additional protective measures including
to stay at home at all times and avoid all face-to-face contact for at least
12 weeks?’
Statistical methods
Data were extracted on 7 September 2020 and analysed using
Stata version 16. Continuous variables were reported using
means (SD), and categorical/dichotomous variables as num-
bers and percentages. To account for partially completed sur-
veys, respondents who completed more than 50% of variables
were included. Individuals completing CORE-UK and PsoPro-
tectMe were classified as having a primary diagnosis of RMD
and psoriasis, respectively.
We characterized the demographic, socioeconomic and dis-
ease-specific factors associated with the primary outcome of
shielding behaviour in the pandemic. The key exposure mea-
sure was IMID treatment type in the pandemic, comprising
three mutually exclusive categories (Table S2; see Supporting
Information):
1 Targeted therapy: biologics and JAK inhibitors [tumour
necrosis factor (TNF) inhibitors: abatacept, adalimumab,
certolizumab pegol, etanercept, golimumab, infliximab,
rituximab; interleukin (IL)-17 inhibitors: brodalumab,
ixekizumab, secukinumab; IL-12/IL-23p40 or IL-23p19
inhibitors: guselkumab, risankizumab, tildrakizumab,
ustekinumab; IL-6 inhibitors: sarilumab, tocilizumab; JAK
inhibitors: baricitinib, tofacitinib].
2 Standard systemic therapy: acitretin, apremilast, azathio-
prine, chloroquine, ciclosporin, dexamethasone, fumaric
acid esters/dimethylfumarate, hydroxychloroquine,
leflunomide, methotrexate, mycophenolate mofetil, pred-
nisolone, sulfasalazine, tacrolimus.
3 No systemic therapy.
Patients on combination targeted and standard systemic
therapy were included in the targeted therapy group, and sur-
veys with missing treatment data were excluded. Apremilast
was included in the standard systemic therapy group because
in clinician-reported registry analyses it was not grouped with
biologics (unlike JAK inhibitors).17,18
After excluding participants who self-reported current or
prior confirmed/suspected COVID-19, associations with shield-
ing status were assessed using: (i) a minimally adjusted logistic
regression model including age and sex covariates; and (ii) a
fully adjusted model including a consensus list of covariates
selected a priori as potentially influential on shielding behaviour
on the basis of expert clinical opinion and existing evidence.20
Treatment was included as a categorical variable in the fully
adjusted model, with no systemic therapy as the reference
group. Country of residence was included as a cluster variable.
A count of the number of comorbidities was generated. This
was converted into a binary variable for analyses according to
consensus clinical expert opinion of the study group: those with
one or more comorbidity vs. those with no comorbidities.
Two sensitivity analyses were performed on the fully
adjusted multivariable regression models: (i) multiple imputa-
tion using iterative chained equations with 20 sets of imputed
data to account for missing covariate data; (ii) exclusion of
respondents on no systemic therapy, with standard systemic
therapy becoming the reference group. Adherence data was
included as a covariate in this model.
As the COVID-19 pandemic progressed in countries over
different time periods, we hypothesized that the impact of
time on the relationship between treatment and shielding
behaviour would vary between countries. To explore this,
unadjusted estimates of shielding over time by treatment
group were plotted for UK and non-UK survey respondents.
Based on these plots we re-ran the multivariable model with
UK respondents only including time as an interaction term
with treatment, and as a fixed covariate, with a comparison of
model fit. Time was converted to a binary variable, before or
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after 30 June. Shielding in the UK appeared to decrease after
this date, which also coincided with the reopening of hospi-
tality businesses (e.g. restaurants) across the UK.
To characterize international variations in shielding behaviour,
a mixed-effects logistic regression model was executed with
country of residence as a random effect. The random effect cap-
tures the difference between national and overall sample means,
enabling estimation of case-mix adjusted rates. The national
effects on shielding were visualized using a caterpillar plot.21
Results
Demographic, socioeconomic and clinical characteristics
of study participants
Self-reported data from 3720 individuals with a primary diagno-
sis of RMD (851, 229%) or psoriasis (2869, 783%, taking
account of missing data) were available from 74 countries [in-
cluding UK (2578, 694%), Portugal (200, 54%), USA (165,
44%)]; for demographic, clinical and socioeconomic
descriptions see Table 1. Survey completion rates were high,
with a median of 94% of covariates of interest completed (in-
terquartile range of 89–95). A total of 650 surveys (17%) had
100% data completion.
Of the participants, 2299 (618%) participants were not
receiving a systemic agent for their psoriasis or RMD, 924
(248%) were receiving targeted therapies and 497 (134%)
standard systemic agents. The three treatment groups had
similar baseline characteristics including age, ethnicity, mean
number per household and comorbidities. Nonadherence was
also similar: 90 of 495 (182%) patients in the standard sys-
temic therapy group reported nonadherence against medical
advice, compared with 138 of 923 (150%) receiving tar-
geted therapy. Of 257 (71%) participants who self-reported
suspected or confirmed COVID-19, 80 (311%) were receiv-
ing a targeted therapy, 46 (179%) a standard systemic agent
and 131 (510%) no systemic treatment. A lower proportion
of those with COVID-19 reported shielding (143 of 257,
556%), compared with those without COVID-19 (2051 of
3352, 612%).








Total, n 3720 2299 497 924
Shielded, n (%)a 2262 (608) 1360 (592) 292 (588%) 610 (660%) < 0001 0
Advised to shield, n (%), UK only 1092 (424%) 523 (316%) 164 (514%) 405 (672%) < 0001 4
UK resident, n (%) 2578 (694%) 1656 (721%) 319 (646%) 603 (652%) < 0001 7
Male sex, n (%) 1174 (316%) 632 (275%) 158 (318%) 384 (416%) < 0001 2
Age in years, mean (SD) 492 (150) 493 (157) 490 (148) 490 (132) 084 25
Ethnicity, n (%) < 0001 0
White ethnicity 2990 (804%) 1856 (807%) 386 (777%) 748 (810%)
Hispanic or Latino 158 (42%) 95 (41%) 29 (58%) 34 (37%)
South Asian 127 (34%) 69 (30%) 23 (46%) 35 (38%)
Japanese 90 (24%) 29 (13%) 18 (36%) 43 (47%)
Black African/Caribbean/American 86 (23%) 68 (30%) 6 (12%) 12 (13%)
Other 269 (72%) 182 (79%) 35 (70%) 52 (56%)
Body mass index, mean (SD) 274 (61) 268 (58) 277 (60) 288 (65) < 0001 301
Alcohol > 14 units a week, n (%) 484 (136%) 291 (134%) 57 (120%) 136 (151%) 024 168
Current smoker, n (%) 460 (131%) 259 (121%) 69 (146%) 132 (148%) 0076 207
Full-time employment, n (%) 1664 (447%) 951 (414%) 223 (449%) 490 (530%) < 0001 0
Number in household, mean (SD) 27 (17) 27 (16) 29 (18) 27 (18) 019 9
Key worker, n (%) 985 (266%) 585 (256%) 146 (294%) 254 (276%) 016 15
Diagnosis, n (%) < 0001 54
Psoriasis 2869 (783%) 1539 (686%) 462 (930%) 868 (939%)
Inflammatory arthritisb 529 (144%) 465 (207%) 23 (46%) 41 (44%)
Connective tissue disease 127 (35%) 113 (50%) 9 (18%) 5 (05%)
Axial spondyloarthritis 85 (23%) 75 (33%) 1 (02%) 9 (10%)
Other 56 (15%) 53 (24%) 2 (04%) 1 (01%)
COVID-19 diagnosis, n (%) 257 (71%) 131 (58%) 46 (97%) 80 (90%) < 0001 111
One or more comorbidity, n (%) 1651 (444%) 949 (413%) 224 (451%) 478 (517%) < 0001 0
Anxiety, n (%) 958 (272%) 605 (281%) 138 (292%) 215 (239%) 0032 197
Depression, n (%) 925 (262%) 593 (275%) 127 (269%) 205 (228%) 0024 196
aShielded refers to participants who quarantined and self-isolated; binflammatory arthritis included any participant with a diagnosis of
rheumatoid arthritis or psoriatic arthritis.
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Risk-mitigating behaviour differed by treatment type
Overall, 2262 participants (608%) reported shielding. Of
1632 participants self-reporting shielding in the UK, only 899
(551%) reported being specifically advised to shield (no data
on shielding advice were available for non-UK participants). A
greater proportion of those receiving targeted therapies (610
of 924, 660%) reported shielding compared with those
receiving standard systemic agents (292 of 497, 588%) or no
systemic therapy (1360 of 2299, 592%).
After excluding those with self-reported COVID-19, we
used logistic regression models to investigate the observed dif-
ferences in shielding by IMID treatment type. Compared with
the reference group of no systemic therapy, an age- and sex-
adjusted model for shielding behaviour estimated an odds
ratio (OR) of 100 [95% confidence interval (CI) 081–123]
for those receiving standard systemic agents. In contrast, a sig-
nificant association with shielding was observed for those
receiving targeted therapies (OR 134, 95% CI 113–159)
(Figure 1).
A fully adjusted multivariable logistic regression analysis
was performed with a categorical treatment exposure variable:
(i) targeted therapy, (ii) standard systemic therapy, (iii) no
systemic therapy. The no systemic therapy group was used as
the reference. Use of targeted therapy was associated with
shielding compared with no systemic therapy (OR 163, 95%
CI 135–197). Standard systemic therapy (OR 117, 95% CI
089–153) did not have a significant association with shield-
ing. There were associations with shielding for RMD (OR
137, 95% CI 127–148), male sex (OR 114, 95% CI 105–
124), comorbidity burden (defined as >1 comorbidity, OR
1.43, 95% CI 1.15-1.78), obesity (OR 137, 95% CI 123–
154) and a positive anxiety or depression screen (OR 157,
95% CI 136–180) (Figure 2). In contrast, shielding was
inversely associated with smoking (OR 073, 95% CI 063–
085), full-time employment (OR 066, 95% CI 049–088),
at least four household members (OR 078, 95% CI 065–
093) and key worker status (OR 055, 95% CI 044–068).
No association was found with age (OR 100, 95% CI 099–
100) or white ethnicity (OR 085, 95% CI 062–117).
Multivariable model sensitivity analyses
To account for missing data (Table 1), the multivariable
model was rerun following multiple imputation. The magni-
tude and direction of associations did not change substantially
(Table S3; see Supporting Information).
The model was also rerun excluding respondents on no sys-
temic therapy, using standard systemic therapy as the refer-
ence group. The association between targeted therapy and
shielding was preserved (OR 139, 95% CI 123–156). Ther-
apy nonadherence was not associated with shielding
(Table S4; see Supporting Information).
The influence of time (survey completion date) on shield-
ing behaviour was explored across treatment groups. Estimated
shielding behaviour generally decreased over time; however,
time had a differential impact in the UK compared with non-
UK countries (Figures S1 and S2; see Supporting Information).
The multivariable model was therefore rerun with UK respon-
dents only, first including time as a fixed covariate and sec-
ondly as an interaction term with treatment. The association
between targeted therapy and shielding was preserved, with a
better model fit for the interaction term (further details in
Tables S5–S7; see Supporting Information).
Figure 1 Age- and sex-adjusted associations with shielding. Each covariate was run as a predictor for shielding, adjusted for age and sex. Survey
responders who were UK residents were asked if they had received an NHS letter advising them to shield, which was associated with shielding,
odds ratio of 47 (95% confidence interval 39–56). Standard therapy and biologic therapy were both compared with no systemic therapy as a
reference group. Obesity, defined as a body mass index greater than 30. RMD, rheumatic and musculoskeletal disease.
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The multivariable model was also rerun limiting shielding
to only those who quarantined (i.e. option 1 of survey ques-
tion on risk-mitigating behaviour). The direction of the asso-
ciations was preserved.
There was modest variation in risk-mitigating behaviour
across countries
A greater proportion of participants in the UK reported shield-
ing compared with those elsewhere (633% vs. 550%). How-
ever, UK participants were also less likely to receive a targeted
therapy (234% vs. 284%). A mixed-effects model further
showed modest variation around the sample mean in the pro-
portion shielding in different countries, indicating broadly
similar risk-mitigating behaviours (Figure 3). Shielding was
more prevalent in the UK, Canada and Argentina, but less
prevalent in Portugal and Japan.
Discussion
We present global self-reported data on risk-mitigating beha-
viours in 3720 individuals with inflammatory joint and skin
disease across 74 countries. Established risk factors for severe
COVID-19 outcome including male sex, obesity and comor-
bidity burden were associated with stringent risk-mitigating
behaviour (classified here under the umbrella term ‘shielding’,
encompassing self-reported shielding, quarantine, staying
home or distancing within the home). Notably, use of tar-
geted therapies (biologics and JAK inhibitors) was associated
with shielding in comparison with no systemic therapy or
standard systemic therapy. Although the differences in shield-
ing behaviours across treatment groups in UK respondents
were preserved when time was used as an interaction term,
the observed decline in estimated shielding behaviour over
time may help inform updated public health guidelines as the
pandemic continues.
Our dataset is based on a large sample of individuals self-re-
porting RMD and psoriasis. Because there was no healthcare
professional/record validation of survey responses, it is reas-
suring that key risk factors for severe COVID-19 in the general
population such as male sex and obesity were associated with
shielding. This is in keeping with public health messaging
during the pandemic and indicates a representative and gener-
alizable sample. Shielding was recommended in groups of
individuals deemed at higher risk7,9 on the premise that this
would reduce the risk of COVID-19 transmission. More
recently, evidence has emerged indicating shielding may also
result in a less severe course of COVID-19 by reducing the
frequency and intensity of exposures to SARS-CoV-2, thus
lowering the infectious dose.22 There is a growing body of
evidence indicating that SARS-CoV-2 viral load positively cor-
relates with disease severity,23,24 and that in animal models,
greater SARS-CoV-2 dose at exposure correlates with higher
viral load and worse outcomes.25
Notably, increasing age was not associated with shielding
behaviour in our dataset (despite an even spread of ages and
105% of our dataset being over age 70 years). This finding is
in keeping with a recent international study of 8317 individu-
als from the general population showing that age did not pre-
dict whether individuals took health precautions (mask
wearing, social distancing, handwashing, staying home).20
Instead, beliefs that taking health precautions are effective and
a concern for one’s own health were important predictors.
Consistent with this, we identified an association between
shielding and anxiety/depression. A larger proportion of par-
ticipants also reported shielding compared with those advised
to shield, which may reflect the elevated rates of self-reported
anxiety. Anxiety and depression have also been reported in
Figure 2 Fully adjusted model identifying associations with shielding. Covariates were determined a priori by an expert panel of collaborators.
Country of residence was included as a cluster variable. Biologic therapy was compared with no systemic therapy as a reference group. Obesity,
defined as a body mass index greater than 30. RMD, rheumatic and musculoskeletal disease.
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previous observational studies, underscoring the mental health
burden of the pandemic (which may at least in part be due to
the impact of social isolation).26–28 While this finding sug-
gests accurate and representative data capture, more data are
required on the severity and temporality of anxiety and
depression.
Our study indicates a greater likelihood of shielding overall
in individuals with a primary diagnosis of RMD compared
with psoriasis; however, the reasons underlying this are not
clear. It may be attributable to differences in illness percep-
tion,29 use of treatments and prevalence of comorbidities.
IMID-specific COVID-19 risks are unknown, and neither RMD
nor psoriasis were included in WHO and national public
health shielding recommendations per se.7,9 The reasons
underlying differences in shielding behaviours between treat-
ment groups, including patient perceptions of COVID-19 risk,
also warrant further study. Although there is a paucity of data
on treatment-related beliefs in psoriasis, recent single-centre
cross-sectional patient survey data in inflammatory bowel dis-
ease indicate patients perceive biologics to be riskier than
other therapies.29 These perceptions may influence shielding
behaviours and are important to address during patient–clini-
cian interactions.
Our global data on shielding behaviour builds on the find-
ings from a recent single-centre audit of 1693 UK patients
with rheumatic diseases.26 Of these, 46% self-reported shield-
ing; however, shielding among different treatment groups was
not explored. In line with our findings, the audit found that a
lower proportion of individuals with COVID-19 shielded
(39%) compared with those without COVID-19 (47%). Our
study also complements emerging findings from international
clinician-reported registries, indicating differences in COVID-
19 outcomes between different treatment types. Among 600
patients with rheumatic diseases and COVID-19 reported to
the COVID-19 Global Rheumatology Alliance registry,17 bio-
logic/targeted synthetic systemic drug use was associated with
lower odds of being hospitalized compared with patients
receiving no systemic therapies. This effect was largely driven
by TNF inhibitors as most patients on biologics were receiving
this subgroup. A decreased risk of hospitalization or death was
also associated with TNF inhibitor biologics compared with
no treatment among 525 patients with inflammatory bowel
disease and COVID-19 reported to SECURE-IBD (Surveillance
Epidemiology of Coronavirus Under Research Exclusion for
Inflammatory Bowel Disease).16 In contrast, the standard sys-
temics sulfasalazine or 5-aminosalicylate were associated with
a higher risk of hospitalization or death. Our previous study
of 374 patients with psoriasis and COVID-19 reported to the
PsoProtect registry further suggested an association between
biologics (pooled data on TNF, IL-17 and IL-23 inhibitors)
and reduced risk of hospitalization, compared with standard
systemic therapies.18 Although exploration of possible biologi-
cal mechanisms underlying these associations is warranted
(e.g. cytokine-targeted biologics may attenuate a severe sys-
temic inflammatory response to COVID-1930), our current
study highlights shielding behaviour as an important unmea-
sured potential mediator in these datasets. The differences in
shielding behaviours across treatments supports the notion that
greater protective shielding behaviour (resulting in a lower
infectious dose of SARS-CoV-2) in those receiving targeted
therapies may account, at least in part, for the observed associ-
ations. Thus, conclusions from clinician-reported registry data
about medication-related COVID-19 risk should be interpreted
in this context, and further research efforts are required to
quantify potential mediation through shielding.
A greater proportion of participants from the UK reported
shielding compared with those elsewhere, which may reflect
cross-national differences in public health messaging.
Figure 3 Caterpillar plot of observed and estimated risk-mitigating behaviour, by nation. The grey markers are the observed national proportions
of survey respondents who shielded. The blue markers are the predicted random national effect on shielding from a mixed-effects model, with
95% confidence intervals in red. The black horizontal line represents the overall mean.
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However, these data should be interpreted with caution as our
dataset is dominated by UK participants. Due to limited cap-
ture of socioeconomic data, we were unable to fully adjust for
this confounder in the analysis; however, we did identify that
household density and full-time employment were inversely
associated with shielding. Both shielding behaviour and clini-
cal decision-making around systemic therapies globally (in-
cluding access to medications) may be affected by
socioeconomic variables such as income and education,31,32
which may in turn influence outcome of COVID-19.4 Linkage
between health, social, behavioural and employment data
should thus be prioritized in future research.
Collecting data via an online survey may have limited partici-
pation to more tech-literate individuals and those more con-
nected to media. The study sample was mostly female (as
expected in survey-based studies), of white ethnicity, and their
diagnoses were self-reported, which further limits the general-
izability of the results. Ascertainment bias may overestimate the
overall proportion shielding, because those more concerned
about COVID-19 risk may be more likely to participate. Our
sample, in which a greater proportion reported receiving tar-
geted therapies compared with standard systemic agents, may
not be representative of patients receiving systemic therapies
more broadly. A disparate group of medications is also classified
together as standard systemic agents. Potential selection bias
may be addressed through systematic recruitment of partici-
pants enrolled in pharmacovigilance registries. Future linkage to
registry and healthcare records may also validate self-reported
demographic and clinical characteristics.
Shielding of at-risk individuals remains a global public
health priority. Our study indicates that use of targeted thera-
pies is associated with shielding in individuals with RMD and
psoriasis, compared with no systemic treatment or standard
systemic agents. This may contribute to the reported lower
risk of adverse COVID-19 outcomes associated with targeted
therapies reported by IMID registries. The observed differences
in shielding across treatment groups, IMIDs, nations and time
may inform future updates of public health recommendations
for COVID-19 risk-mitigating behaviours. Capture and consid-
eration of risk-mitigating behaviour is important in future
studies of COVID-19 risk across people with IMIDs and on
different types of systemic treatments.
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